{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tumor+peptide+vaccine&page=12", "query": { "intervention": "tumor peptide vaccine", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 465, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tumor+peptide+vaccine&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tumor+peptide+vaccine&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:01:51.515Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02709993", "title": "Consolidation Therapy in Patients With Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Hematologic Malignancies" ], "interventions": [ { "name": "TAPA-pulsed DC vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kiromic BioPharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-07-28", "completion_date": "2020-10-31", "has_results": false, "last_update_posted_date": "2019-10-14", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02709993" }, { "nct_id": "NCT00006113", "title": "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "recombinant CD40-ligand", "type": "BIOLOGICAL" }, { "name": "recombinant interferon gamma", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-4", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "therapeutic tumor infiltrating lymphocytes", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "Candida albicans skin test reagent", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "1999-06", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006113" }, { "nct_id": "NCT02823990", "title": "TG4010 and Nivolumab in Patients With Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-Small Cell Lung Carcinoma", "Stage I Non-Small Cell Lung Cancer", "Stage II Non-Small Cell Lung Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "TG4010", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Megan Daly, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-12-14", "completion_date": "2021-02-24", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 4, "location_summary": "Duarte, California • Sacramento, California • San Diego, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02823990" }, { "nct_id": "NCT05025488", "title": "Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis", "Essential Thrombocythemia", "MPN" ], "interventions": [ { "name": "Peptide-based vaccine", "type": "DRUG" }, { "name": "Poly ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marina Kremyanskaya", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-04-04", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025488" }, { "nct_id": "NCT00665002", "title": "Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "WT-1", "type": "BIOLOGICAL" }, { "name": "Montanide", "type": "DRUG" }, { "name": "Sargramostim (GM-CSF)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2008-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2015-02-27", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00665002" }, { "nct_id": "NCT00363012", "title": "Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "HER-2/neu intracellular domain protein", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "Sterile water placement", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2006-04", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363012" }, { "nct_id": "NCT00019214", "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-04", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019214" }, { "nct_id": "NCT00488592", "title": "Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Acute Myeloid Leukemia (AML)", "Chronic Myeloid Leukemia (CML)" ], "interventions": [ { "name": "WT1:126-134", "type": "BIOLOGICAL" }, { "name": "PR1:169-177 Peptide", "type": "BIOLOGICAL" }, { "name": "GM-CSF (Sargramostim)", "type": "DRUG" }, { "name": "Montanide adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 10, "start_date": "2007-06", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488592" }, { "nct_id": "NCT05378464", "title": "Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Dendritic Cell (DC1) Vaccine", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pepinemab", "type": "DRUG" }, { "name": "T-Cell therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2022-05-31", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05378464" }, { "nct_id": "NCT06782932", "title": "Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "AGEN2373", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX", "type": "DRUG" }, { "name": "AGEN2373 (RP2D)", "type": "DRUG" }, { "name": "mKRASvax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2025-05-27", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-14T01:01:51.515Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06782932" } ] }